This article is sponsored by Phenomenex. As antibody-drug conjugates (ADCs) continue to emerge as a pivotal approach in targeted cancer therapeutics, the demand for precise and efficient characterisation methods is increasing. Determining the average drug-to-antibody ratio (DAR) is a key quality attribute for ADCs and conventional analysis via… Read More
An opinion by Dr Ioannis Papasotiriou. This article is sponsored by RGCC International. How is a new drug developed in oncology? While this may seem like a simple question, it is important to recognise that the process is far more complex than it initially… Read More
This article is sponsored by Evoke. Dominic Elliston, Managing Director of Evoke Galliard and Evoke Incisive Health, shares his take on how effective clinical trial communications is the key to expediting the delivery of new and extraordinary treatments. Tell us about yourself, Dominic. My name is… Read More
This article is sponsored by Collaborative Drug Discovery (CDD). It is no secret that getting a new drug to market is a long, complicated, and costly process that can take years to complete. However, having the right informatics tools in place can make a substantial difference by… Read More
